Shandong Boan Biotechnology’s Dulaglutide Injection Approved for Marketing in China

Shandong Boan Biotechnology Company., Limited. Class H ( (HK:6955) ) has shared an update.

Shandong Boan Biotechnology Co., Ltd. has received marketing approval from China’s National Medical Products Administration for Boyouping® (Dulaglutide Injection), a biosimilar to Trulicity®, intended for glycemic control in adults with type 2 diabetes. This approval marks Boyouping® as the first dulaglutide biosimilar approved for marketing globally, with no other similar biosimilars in the BLA stage in China. The company has partnered with Shanghai Pharmaceutical Co., Ltd. to commercialize the drug in China, addressing the growing diabetic population and unmet demand for long-acting GLP-1 drugs. Boyouping® demonstrated equivalent efficacy and safety to Trulicity® in clinical trials, and its approval is expected to enhance the accessibility and market coverage of GLP-1 drugs in China.

More about Shandong Boan Biotechnology Company., Limited. Class H

Shandong Boan Biotechnology Co., Ltd. is a biotechnology company based in China, focusing on the development of biosimilar drugs. The company specializes in the creation of complex peptide-Fc fusion proteins and has expertise in chemistry, manufacturing, and controls (CMC) development, particularly for biosimilars.

Average Trading Volume: 23,347,648

Technical Sentiment Signal: Buy

Current Market Cap: HK$10.34B

For detailed information about 6955 stock, go to TipRanks’ Stock Analysis page.